

"Pharmacological study on the potential effect of piceatannol on cisplatin- induced nephrotoxicity in rats"

Thesis presented by

Sara Abdel Moneim Abdel Zaher Wahdan

M.Sc., Ain Shams University (2014)

Assistant Lecturer of Pharmacology and Toxicology,

Faculty of pharmacy, Ain Shams University.

**Submitted for partial fulfillment of PhD degree in
Pharmaceutical Sciences to Department of Pharmacology and
Toxicology, Faculty of Pharmacy, Ain Shams University.**

Under the supervision of

Dr. Ebtehal El-Demerdash Zaki

Professor and head of Pharmacology and Toxicology Departement

Faculty of Pharmacy, Ain Shams University.

Dr. Samar Saad El-Deen Azab

Associate Professor of Pharmacology and Toxicology,

Faculty of Pharmacy, Ain Shams University.

Dr. Doaa Ahmed El-Sherbini

Lecturer of Pharmacology and Toxicology,

Faculty of Pharmacy, Ain Shams University.

Faculty of Pharmacy

Ain Shams University

(2017)

"دراسة فارماكولوجية للتأثير المحتمل لمركب بيسانتول في تسمم الكلي المحدث بدواء سيسبلائين في الجرذان"

رسالة مقدمة من الصيدلانية

سارة عبد المنعم عبد الظاهر وهدان

ماجستير علوم صيدلية . جامعة عين شمس (2014)

مدرس مساعد بقسم الأدوية والسموم . كلية الصيدلة . جامعة عين شمس

كجزء للحصول علي درجة الدكتوراة في العلوم الصيدلية

(علم الأدوية والسموم)

تحت إشراف

أ.د/ إبتهاال الدمرداش زكي

أستاذ و رئيس قسم الأدوية والسموم . كلية الصيدلة .

جامعة عين شمس

د/ سمر سعد الدين عزب

أستاذ مساعد علم الأدوية والسموم . قسم الأدوية والسموم . كلية الصيدلة .

جامعة عين شمس

د/ دعاء احمد مختار

مدرس علم الأدوية والسموم . قسم الادوية والسموم، كلية الصيدلة .

جامعة عين شمس

كلية الصيدلة

جامعة عين شمس 2017

Abstract

Cisplatin induced nephrotoxicity is a major side effect limiting its chemotherapeutic use. We investigated whether piceatannol (PIC) can protect against cisplatin-induced nephrotoxicity in rats and the potential underlying mechanisms. A single dose of cisplatin (7mg/kg i.p.) was used to induce nephrotoxicity and PIC was given in different daily doses (5, 10 and 20 mg/kg i.p.), for seven days starting two days before cisplatin injection. Cisplatin significantly increased blood urea nitrogen and serum creatinine levels and induced tubular degeneration, hemorrhage and cast formation. PIC at dose 10 mg/kg was effective in preventing these alterations. In subsequent mechanistic study, PIC (10 mg/kg i.p.) reversed cisplatin-induced kidney injury molecule 1 and neutrophil gelatinase associated lipocalin and ameliorated cisplatin-induced oxidative stress, inflammation and apoptosis. PIC inhibited cisplatin-induced lipid peroxidation and glutathione depletion. Additionally, PIC reversed cisplatin-induced reduction in the gene expression of nuclear factor E2-related factor 2 and the relative mRNA level of antioxidant related genes; hemoxygenase-1, cysteine ligase catalytic and modifier subunits, as well as superoxide dismutase and glutathione-S-transferase activities. Furthermore, cisplatin proinflammatory response was reduced by PIC treatment as evidenced by decreased tissue levels of interleukin-1 β , tumor necrosis factor- α , cyclooxygenase-2 and inducible nitric oxide synthase, as well as reversing nuclear factor kappa-B activation. Moreover, PIC suppressed cisplatin-induced apoptosis by decreasing p53 and cytochrome C expression and caspase-3 activity. Furthermore, we also investigated PIC ability to modify cisplatin cytotoxicity on two different cancer cell lines; Human hepatocellular carcinoma and Prostate carcinoma cell lines. PIC enhanced cisplatin cytotoxic effects by lowering its IC₅₀ values in both cell lines. Therefore PIC has the potential for ameliorating cisplatin-induced renal injury while improving its cytotoxic activity.

Key words: Cisplatin, piceatannol, nephrotoxicity, oxidative stress, inflammation, apoptosis.

Acknowledgements

*Most heartfelt thanks are due to **Dr. Ebtahal El Demerdash**, Professor of Pharmacology and Toxicology, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, who has made this work possible by her great effort, continuous guidance, support and indispensable help in practical work and thesis writing. In fact, she was more than a supervisor, she never stopped supporting and encouraging me. Her precious advices were always pushing me forward.*

*I am greatly thankful to **Dr.SamarSaadElDeenAzab**, Associate Professor of Pharmacology and Toxicology, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University. I am deeply grateful for her continuous support, guidance as well as tremendous effort and indispensable help in the practical work and thesis writing.*

*I wish to express my appreciation and gratitude to **Dr.Doaa Ahmed El-Sherbini**, Lecturer of Pharmacology and Toxicology, Department of Pharmacology and Toxicology,,Ain Shams University, for her guidance, kind cooperation and discussion throughout the work.*

*I would like to thank **Dr. Ahmed Esmat and Dr. EmanMantawy**, lecturers of Pharmacology and Toxicology, **MSc PharmacistReemTarek** Assistant lecturer of Pharmacology and Toxicology, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, for their help in the practical work.*

It is my great pleasure to thank all members of Pharmacology and Toxicology Department, Faculty of Pharmacy, Ain Shams University and every person in my Faculty who supported me and helped me in my way.

Finally, but of great importance, I wish to express my deep gratefulness and thanks to my family; for their continuous moral and emotional support.

List of Contents

<i>Subject</i>	<i>Page NO.</i>
<i>1- List of abbreviations</i>	I
<i>2- List of tables</i>	V
	VII
<i>3- List of figures</i>	1
<i>4- Introduction</i>	
<i>-Cisplatin</i>	1
-Discovery and history	1
	2
-Chemistry	4
-	8
Pharmacodynamics	10
-Pharmacokinetics	
-Toxicity	
	12
<i>-Nephrotoxicity</i>	
-Risk factors	12
-Clinical manifestations	14
-Pathophysiology	15
	25
-General measures to prevent	
	27
cisplatin-induced nephrotoxicity	
-Nephroprotective strategies	
<i>-Piceatannol</i>	31
-Source	31

	32
-Chemistry	33
-	35
Pharmacodynamics	42
-Pharmacokinetics	
-Toxicity	
5- Aim of the work	43
6- Materials and Methods	44
7-Results	109
8- Discussion	155
9- Summary and Conclusions	163
10- References	167
11- Arabic summary	

Figure No.	Figure title	Page No.
I	Chemical structure of cisplatin and its inactive trans-isomer (transplatin)	3
II	Formation of DNA-Pt adducts	5
III	Overview of the pathophysiological events in cisplatin nephrotoxicity.	16
IV	Inflammatory response in cisplatin nephrotoxicity	21
V	Apoptotic pathways activated by cisplatin in renal tubular cells.	24
VI	p53 signaling cisplatin-induced kidney injury.	25
VII	Chemical structure of piceatannol	32
VIII	Resveratrol metabolism to piceatannol	34
IX	Schematic diagram for the experimental design of the current study	48
X	Standard calibration curve of kidney injury molecule 1 (KIM-1)	61
XI	Standard calibration curve Neutrophil Gelatinase Associated Lipocalin (NGAL)	65
XII	Standard calibration curve of tumor necrosis factor - α (TNF- α)	75
Figure No.	Figure title	Page No.
XIII	Standard calibration curve of interleukin-1 β (IL-1 β)	79
XIII	Standard calibration curve of caspase-3	83
XV	Melting curves of GAPDH, HO-1, GCLC, GCLM, p53 and OCT-2	91
XVI	Amplification plots of GAPDH, HO-1, GCLC, GCLM, p53 and OCT-2	91

XVII	Standard calibration curve of protein	100
XVIII	Schematic diagram representing the way of preparation of the tissue samples for ICP	103
1	Effects of different doses of PIC and/or cisplatin on body weight, absolute kidney weight and relative kidney weight	112
2	Effects of different doses of PIC and/or cisplatin on serum creatinine and BUN	113
3	Effects of different doses of PIC on cisplatin-induced histological alterations of the kidney tissue	115
4	Effect of PIC and/or cisplatin on serum KIM-1 and NGAL	119
5	Representative electronmicrograph ultrathin sections of the kidney	121

Figure No.	Figure title	Page No.
6	Effect of PIC and/or cisplatin on reduced glutathione level (GSH) and lipid peroxidation expressed as malondialdehyde level (MDA)	124
7	Effect of PIC and/or cisplatin on Nrf2 expression	126
8	Effect of PIC and/or cisplatin on HO-1 mRNA levels expressed as relative quantification (RQ) compared to the control group	129
9	Effect of PIC and/or cisplatin on GCLC and GCLM mRNA levels expressed as relative quantification (RQ) compared to the control group	130
10	Effect of PIC and/or cisplatin on GST and SOD levels	131
11	Effect of PIC and/or cisplatin on TNF- α and IL-1 β levels	133

12	Effect of PIC and/or cisplatin on Nf-kB expression	135
13	Expression of iNOSby immunohistochemical staining	137
14	Expression of COX-2 by immunohistochemical staining	139
15	Expression of cytochrome C by immunohistochemical staining	142
Figure No.	Figure title	Page No.
16	Effect of PIC and/or cisplatinon P53 mRNA level expressed as relative quantification (RQ) compared to the control group	145
17	Effect of PIC and/or cisplatinon caspase-3 activity	145
18	Effect of PIC and/or cisplatin on OCT-2 expression and platinum content	147
19	(A)Cytotoxicity curve of various concentrations of cisplatin in HepG2 cancer cell line. (B)Cytotoxicity curve of various concentrations of cisplatin in PC3 cancer cell line	150
20	(A)Cytotoxicity curve of various concentrations of PIC in HepG2 cancer cell line. (B)Cytotoxicity curve of various concentrations of cisplatin in PC3 cancer cell line	152
21	(A)Cytotoxicity curve of various concentrations of cisplatinalone or in combination with 4 μ M PIC in HepG2 cancer cell line. (B)Cytotoxicity curve of various concentrations of cisplatin alone or in combination with 4 μ M PIC in PC3 cancer cell line	154

ARE	Antioxidant response elements
AIF	Apoptosis inducing factor
ATP	Adenosine triphosphate
BAD	Bcl-2-associated death promoter
Bak	Bcl-2 homologous antagonist/killer
Bax	Bcl-2 associated X protein
BCA	Bicinchoninic acid
Bcl-2	B-cell lymphoma 2
Bcl-xl	B-cell lymphoma-extra large
BSA	Bovine serum albumin
BUN	Blood urea nitrogen
CAT	Catalase
CK	Creatinine kinase
COX-2	Cyclooxygenase- 2
Ctr-1	Copper transporter-1
Ct	Cycle threshold
DMSO	Dimethyl sulfoxide
DNA	Deoxyribonucleic acid
DSS	Dextran sodium sulfate
DTNB	5,5'-dithio-bis (2-nitrobenzoic acid)
DW	Distilled water
ECL	Enhanced luminol based chemiluminescence

ER	Endoplasmic reticulum
ERα	Estrogen receptor α
ERβ	Estrogen receptor β
EDTA	Ethylene-diaminetetraacetic acid
GGT	Gamma-glutamyltranspeptidase
GFR	Glomerular filtration rate
GLUT-4	Glucose transporter-4
GCLC	Glutamate-cysteine ligase catalytic subunit
GCLM	Glutamate-cysteine ligase modifier subunit
GAPDH	Glyceraldehyde 3-phosphate dehydrogenase
GPx	Glutathione peroxidase
GR	Glutathione reductase
GSH	Reduced glutathione
GSSG	Oxidized glutathione
GST	Glutathione-S-transferase
HO-1	Hemeoxygenase-1
HMG	High motility group
H₂O₂	Hydrogen peroxide
HRP	Horseradish peroxidase
HepG2	Human hepatocellular carcinoma
IgE	Immunoglobulin E
IFN-γ	Interferon- γ

IκB	Inhibitor of kappa B
IKK	IκB kinase
IL	Interleukin
iNOS	Inducible nitric oxide synthase
ICAM-1	Intracellular adhesion molecule-1
IP	Intra-peritoneal
ICP-OES	Inductively Coupled Plasma Optical Emission Spectroscopy
JAK-1	Janus kinase-1
Keap-1	Kelch-like ECH-Associated Protein 1
KIM-1	Kidney injury molecule 1
LDH	Lactate dehydrogenase
LPS	Liopolysaccharide
Maf	Musculoaponeuroticfibrosarcoma
MDA	Melanocyte stimulating hormone
MSC	Mesenchymal stem cells
mRNA	Messenger RNA
MAPK	Mitogen-activated protein kinase
NADH	Nicotinamide adenine dinucleotide
NGAL	Neutrophil gelatinase associated lipocalin
Nrf-2	Nuclear factor E2-related factor 2
NF-κB NO	Nuclear factor kappa B
	Nitric oxide
OCT-2	Organic cation transporter 2

PIC	Piceatannol
Pt	Platinum
PPAR-α	Peroxisome proliferator-activated receptor alpha
Puma	P53 upregulated modulator of apoptosis
PIDD	P53 inducible protein with death domain
RNA	Ribonucleic acid
ROS	Reactive oxygen species
RQ	Relative quantity
RT-PCR	Real time polymerase chain reaction
STAT	Signal transduction and activator of transcription
SYK	Spleen tyrosine kinase
SDS-PAGE	Sodium dodecyl sulfate polyacrylamide gel electrophoresis
SOD	Superoxide dismutase
TBARS	Thiobarbituric acid reactive substances
TLR	Toll like receptor
TGF-β1	Transforming growth factor β 1
TBS	Tris-buffered saline
TBST	Tris-buffered saline with tween
TNF-α	Tumor necrosis factor-alpha
TNFR	Tumor necrosis factor receptor

. Cisplatin

Cisplatin is one of the most potent chemotherapeutic drugs, widely used for cancer treatment. Cisplatin is used alone or in combination with other chemotherapeutic agents for the treatment of a spectrum of specific cancers, including testicular, ovarian, bladder, head and neck, esophageal, small and non-small cell lung. It is also used for breast, cervical, stomach and prostate cancers, as well as Hodgkin's and non-Hodgkin's lymphomas, neuroblastoma, sarcomas, multiple myeloma, melanoma, and mesothelioma (**Miller et al., 2010**).

1.1. Discovery and history

Cisplatin was first synthesized by M. Peyrone in 1844 while its chemical structure was first elucidated by Alfred Werner in 1893. However, the compound gained scientific attention in 1960s, when **Rosenberg et al. (1965)** at Michigan State University, identified certain electrolysis products of platinum electrodes which were able to inhibit cell division of *Escherichia coli*. These initial observations created much interest in the possible use of these products in cancer chemotherapy. In 1968, cisplatin was injected at the non-lethal dose to mice bearing a standard murine transplantable tumor, and caused marked tumor regression (**Rosenberg et al., 1969**).

In 1971, cisplatin was taken for clinical trials by the US National Cancer Institute (NCI). By the end of the 1970s it had earned a place as the key ingredient in the systemic treatment of germ cell cancers. It was the first FDA-approved platinum compound for cancer treatment in 1978 (**Kelland, 2000**). The discovery of cisplatin is considered a corner stone which triggered the interest in platinum and other metal-containing compounds as potential anticancer drugs (**Florea and Büsselberg, 2011**).

1.2. Chemistry

Cisplatin [(CAS No. 15663-27-1), cisplatinum, cis-diamminedichloroplatinum(II)], is a metallic (platinum) compound with a chemical formula: $\text{H}_6\text{Cl}_2\text{N}_2\text{Pt}$. It is a white or deep yellow to yellow-orange crystalline powder at room temperature. It is slightly soluble in water (1 in 1000) and N,N-dimethylformamide, insoluble in alcohol; sparingly soluble in dimethylformamide. A 0.1% solution in 0.9% saline has a pH of 4.5-6.0. The injectable preparation has a pH of 3.5-6.2 (**Dasari and Tchounwou, 2014**).

Cisplatin is stable under normal temperatures and pressures but transform slowly over time to the trans-isomer. Cisplatin has a molecular weight of 301.1 gm/mol, a density of 3.74 g/cm^3 and a melting point of 270°C (**Dasari and Tchounwou, 2014**).

Cisplatin exists as an electro-neutral, four coordinate platinum complex. It has two chloride ion ligands situated adjacent to one another, and two ammonia ligands, in a square (tetragonal) planar structure (**Fig.I**). The anticancer activity of cisplatin is due to the relative ease of substitution of the chlorine ligands with nucleophilic species like nucleic acid bases of a DNA strand. The cis isomer has antitumor activity, while the trans isomer of cisplatin, transplatin, showed no antitumor activity (**Johnstone et al., 2015**).